Genetically interrupting the migration of NRP-1-expressing TAMs to the hypoxic tumor core abrogates their acquisition of pro-tumor functions, instead allowing the induction of anti-tumor T helper 1 (TH1) and cytotoxic T lymphocyte (CTL) responses and a reduction of tumor progression [5,7,9]. The gene discussed is NRP1; the disease is neoplasm.